Maribavir for treating refractory cytomegalovirus infection after transplant

2.1 Maribavir (Livtencity) is indicated for 'the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT)'.

2.2 The dosage schedule is available in the summary of product characteristics for maribavir.

2.3 The list price of 56 x 200 mg maribavir tablets is £11,550 (excluding VAT; company source). The company has a commercial arrangement. This makes maribavir available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.